SGS reveals investment into North American biopharmaceutical testing capabilities

Biopharmaceutical analytical and bioanalytical contract solutions provider, SGS, has revealed it is investing more than $1.7 million to expand its North American biopharmaceutical testing capabilities in Illinois.

The investment will cover both expertise and equipment and will extend the biopharmaceutical testing services offered by SGS’s current US and Canadian life science facilities. Installation of all equipment at the Lincolnshire facility in Illinois is expected to be completed in the first quarter of 2019.

“Because of its strategic geographic location, in what is a rich cluster of biopharmaceutical companies, strengthening the capabilities at the Lincolnshire laboratory will allow SGS to act as a local partner for innovators looking for expertise in biopharmaceutical analysis,” said James Nokes, vice president of US Agriculture, Food and Life at SGS. “SGS maintains its commitment to invest in its network of laboratories to offer integrated solutions, and evolve for both the local and global needs of its clients.”

The site currently offers a range of analytical services and has adapted 313 cubic metres of stability storage in order to meet the lower temperature regulatory requirements for peptides and proteins. This additional investment will allow SGS to offer greater capacity for GMP biologics testing capabilities in North America to better serve its biopharmaceutical clients.